AbbVie to buy Stemcentrx to boost cancer drug portfolio

AbbVie to buy Stemcentrx to boost cancer drug portfolio

REUTERS: AbbVie Inc placed another big bet on new cancer drugs on Thursday with a US$5.8 billion acquisition that could lessen its dependence on arthritis treatment Humira, the world's top selling drug. Shares of AbbVie rose 1.3 percent in afternoon …

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Write a comment

*